The article argues that in securities fraud cases, not only concrete facts like accounting errors or drug rejections can be considered as corrective disclosures, but also changes in analysts' opinions based on these facts. These changes are often shared through written research reports, and should be recognized as important disclosures to compensate defrauded investors.